{"id":"https://openalex.org/W4237513152","doi":"https://doi.org/10.1200/jco.2013.31.6_suppl.263","title":"A novel phase I trial design featuring a two-dimensional dose-finding algorithm optimizing the dose of gemcitabine and doxorubicin with bortezomib in metastatic urothelial carcinoma (UC).","display_name":"A novel phase I trial design featuring a two-dimensional dose-finding algorithm optimizing the dose of gemcitabine and doxorubicin with bortezomib in metastatic urothelial carcinoma (UC).","publication_year":2013,"publication_date":"2013-02-20","ids":{"openalex":"https://openalex.org/W4237513152","doi":"https://doi.org/10.1200/jco.2013.31.6_suppl.263"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2013.31.6_suppl.263","doi":"https://doi.org/10.1200/jco.2013.31.6_suppl.263","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2013.31.6_suppl.263","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5057758356","display_name":"Arlene Odelia Siefker-Radtke","orcid":"https://orcid.org/0000-0002-6328-9599","observed_orcids":["https://orcid.org/0000-0002-6328-9599"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Arlene O. Siefker-Radtke","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040146877","display_name":"Sijin Wen","orcid":"https://orcid.org/0000-0002-6955-2917","observed_orcids":["https://orcid.org/0000-0002-6955-2917"]},"institutions":[{"id":"https://openalex.org/I12097938","display_name":"West Virginia University","ror":"https://ror.org/011vxgd24","country_code":"US","type":"education","lineage":["https://openalex.org/I12097938"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sijin Wen","raw_affiliation_strings":["West Virginia University Health Science Center, Morgantown, WV"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"West Virginia University Health Science Center, Morgantown, WV","institution_ids":["https://openalex.org/I12097938"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067273026","display_name":"Yu Shen","orcid":"https://orcid.org/0000-0002-3899-7868","observed_orcids":["https://orcid.org/0000-0002-3899-7868"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yu Shen","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022268757","display_name":"Kristi Stigall","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kristi Stigall","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059536506","display_name":"David James McConkey","orcid":"https://orcid.org/0000-0003-1971-0638","observed_orcids":["https://orcid.org/0000-0003-1971-0638"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David James McConkey","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5027897588","display_name":"Randall E. Millikan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Randall E. Millikan","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"31","issue":"6_suppl","first_page":"263","last_page":"263"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":0.986299991607666,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":0.986299991607666,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.0034000000450760126,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/metastatic-urothelial-carcinoma","display_name":"metastatic urothelial carcinoma","score":0.902999997138977},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":0.9760000109672546},{"id":"https://openalex.org/keywords/gemcitabine","display_name":"gemcitabine","score":0.996999979019165},{"id":"https://openalex.org/keywords/doxorubicin","display_name":"doxorubicin","score":0.9990000128746033},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.6710000038146973},{"id":"https://openalex.org/keywords/phase-i-trial-design","display_name":"phase I trial design","score":0.7490000128746033},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8610000014305115},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.9319999814033508},{"id":"https://openalex.org/keywords/thrombocytopenia","display_name":"thrombocytopenia","score":0.8790000081062317},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.7519999742507935},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.7889999747276306},{"id":"https://openalex.org/keywords/metastatic-prostate-cancer","display_name":"metastatic prostate cancer","score":0.7229999899864197},{"id":"https://openalex.org/keywords/metastatic-renal-cell-carcinoma","display_name":"metastatic renal cell carcinoma","score":0.9120000004768372},{"id":"https://openalex.org/keywords/proteasome-inhibitors","display_name":"proteasome inhibitors","score":0.7680000066757202}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8058179020881653},{"id":"https://openalex.org/C2780258809","wikidata":"https://www.wikidata.org/wiki/Q414143","display_name":"Gemcitabine","level":3,"score":0.8003756999969482},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.6980016827583313},{"id":"https://openalex.org/C2778496288","wikidata":"https://www.wikidata.org/wiki/Q6931269","display_name":"Mucositis","level":3,"score":0.6845048069953918},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.51747065782547},{"id":"https://openalex.org/C2780192828","wikidata":"https://www.wikidata.org/wiki/Q181257","display_name":"Prostate cancer","level":3,"score":0.45646536350250244},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.42234480381011963},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.4071255326271057},{"id":"https://openalex.org/C11413529","wikidata":"https://www.wikidata.org/wiki/Q8366","display_name":"Algorithm","level":1,"score":0.3833082914352417},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.37224555015563965},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.36492741107940674},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.35305172204971313},{"id":"https://openalex.org/C33923547","wikidata":"https://www.wikidata.org/wiki/Q395","display_name":"Mathematics","level":0,"score":0.11521822214126587}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2013.31.6_suppl.263","doi":"https://doi.org/10.1200/jco.2013.31.6_suppl.263","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2013.31.6_suppl.263","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9922999739646912,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2087535634","https://openalex.org/W2258116442","https://openalex.org/W2017289335","https://openalex.org/W1522557416","https://openalex.org/W2596311534","https://openalex.org/W2256538001","https://openalex.org/W100548313","https://openalex.org/W2983486717","https://openalex.org/W2185085274","https://openalex.org/W2080199075"],"abstract_inverted_index":{"263":[0],"Background:":[1],"Preclinical":[2],"studies":[3],"suggested":[4],"that":[5,352],"bortezomib":[6,26],"(B)":[7],"enhanced":[8],"the":[9,66,79,137,140,145,187,200,243,251,255,258,340,343,349],"activity":[10,241,260,322],"of":[11,25,65,115,126,147,206,218,318,332],"gemcitabine":[12],"and":[13,106,117,120,151,180,194,222,235,293],"doxorubicin":[14],"(GA)":[15],"in":[16,41,108,168,302],"UC;":[17],"thus":[18],"we":[19,142],"sought":[20],"to":[21,60,69,112,122,208,220,339,348],"define":[22],"possible":[23],"combinations":[24,74],"with":[27,55,86,130,246],"this":[28],"doublet.":[29],"We":[30],"employed":[31],"a":[32,53,103,109,113,123,310],"novel":[33],"phase":[34,335],"I":[35,336],"trial":[36,358],"design":[37,337],"systematically":[38],"exploring":[39,154],"doses":[40,155,212,253,324,331],"2":[42],"dimensions.":[43],"The":[44,171,184,225,271,278,316],"method":[45],"estimates":[46],"an":[47,157,247],"isotoxic":[48,158,256],"curve":[49,159],"allowing":[50],"not":[51],"only":[52],"combination":[54,317],"approximately":[56],"equal":[57],"(with":[58],"respect":[59],"single":[61,104],"component":[62,77,105],"MTD)":[63],"contributions":[64],"two":[67],"components":[68],"be":[70],"found,":[71],"but":[72],"also":[73],"emphasizing":[75],"one":[76],"or":[78,178,296],"other.":[80],"Methods:":[81],"Since":[82],"11/06,":[83],"74":[84],"patients":[85,307],"previously":[87],"treated":[88,101],"metastatic":[89],"cancer":[90],"were":[91,229],"enrolled":[92],"(70":[93],"UC,":[94],"3":[95],"prostate,":[96],"1":[97],"renal).":[98],"GA":[99,201,219,275],"was":[100,191,239,261,276,300,354],"as":[102],"given":[107],"fixed":[110],"ratio":[111],"maximum":[114],"900":[116],"50":[118,313],"mg/m2,":[119,196,267],"B":[121,207,214,265],"maximal":[124],"dose":[125,146,164],"1.6":[127],"mg/m2":[128],"IV,":[129],"dosing":[131,338],"every":[132],"14":[133],"days.":[134],"After":[135],"determining":[136],"MTD":[138,185,245,341],"along":[139,156,186,254],"diagonal,":[141],"then":[143],"decreased":[144],"B,":[148],"increasing":[149],"GA,":[150],"vice":[152],"versa,":[153],"aiming":[160],"for":[161,189],"\u2264":[162],"30%":[163],"limiting":[165],"toxicity":[166],"(DLT)":[167],"cycle":[169],"1.":[170],"objective":[172],"response":[173],"rate":[174],"(ORR)":[175],"includes":[176],"PR":[177],"CR,":[179],"excludes":[181],"SD.":[182],"Results:":[183],"diagonal":[188],"GAB":[190,319],"756,":[192],"42,":[193],"1.4":[195],"respectively.":[197],"Doses":[198],"maximizing":[199,213,264,274,325],"(900,":[202],"50)":[203],"required":[204,216],"reduction":[205,217],"1.2":[209],"mg/m2.":[210,224],"Likewise,":[211],"(1.6)":[215],"559":[221],"33":[223],"most":[226,279],"common":[227],"DLT":[228],"thrombocytopenia":[230,285],"14%,":[231],"neutropenic":[232,294],"fever":[233,295],"5%,":[234],"mucositis":[236],"1%.":[237],"There":[238],"minimal":[240,355],"at":[242,323],"on-diagonal":[244],"ORR":[248,268,272],"1/10.":[249],"Of":[250],"tolerable":[252,301],"curve,":[257],"greatest":[259],"seen":[262],"when":[263,273],"(1.5-1.6":[266],"7/12":[269],"(58%)).":[270],"4/10.":[277],"frequent":[280],"\u2265":[281],"G3":[282],"toxicities":[283],"include:":[284],"(26%),":[286,288],"neutropenia":[287],"anemia":[289],"(24%),":[290],"fatigue":[291],"(8%),":[292],"infection":[297],"(12%).":[298],"Treatment":[299],"poor":[303],"renal":[304],"function;":[305],"36":[306],"(49%)":[308],"had":[309],"GFR":[311],"<":[312],"ml/min.":[314],"Conclusions:":[315],"has":[320],"promising":[321],"proteosome":[326],"inhibition,":[327],"despite":[328],"relatively":[329],"low":[330],"GA.":[333],"Traditional":[334],"\"along":[342],"diagonal\"":[344],"would":[345],"have":[346],"lead":[347],"incorrect":[350],"conclusion":[351],"there":[353],"activity.":[356],"Clinical":[357],"information:":[359],"NCT00479128.":[360]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2019,"cited_by_count":2}],"updated_date":"2026-10-01T08:54:57.152042","created_date":"2022-05-12T00:00:00"}